— Know what they know.
Not Investment Advice

PRPH OTC

ProPhase Labs, Inc.
1W: +43.6% 1M: -21.8% 3M: -78.5% YTD: -95.6% 1Y: -99.7% 3Y: -99.9% 5Y: -99.9%
$0.02
+0.00 (+31.67%)
 
Weekly Expected Move ±35.8%
$0 $0 $0 $0 $0
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 44 · $221456 mcap · 14M float · 1.12% daily turnover · Short 34% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.2M
52W Range0.008-6.7
Volume530,584
Avg Volume153,158
Beta0.13
Dividend—
Analyst Ratings
1 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOTed William Karkus
Employees19
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date1994-04-04
626 RXR Plaz
Uniondale, NY 11556
US
215 345 0919
About ProPhase Labs, Inc.

ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.

Recent Insider Trades

NameTypeSharesPriceDate
Karkus Ted William A-Award 500,000 $0.60 2025-09-09
Abenante Carolina 0 — 2025-06-20
Hollenshead Stuart A-Award 500,000 $0.60 2025-02-17
Hirsch Warren A-Award 100,000 $0.60 2025-02-14
GLECKEL LOUIS MD A-Award 100,000 $0.60 2025-02-14

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms